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ABSTRACT
The mechanisms of efficacy for fecal microbiota transplantation (FMT) in treating recurrent
Clostridioides difficile infection (rCDI) remain poorly defined, with restored gut microbiota-bile
acid interactions representing one possible explanation. Furthermore, the potential implications
for host physiology of these FMT-related changes in gut bile acid metabolism are also not well
explored. In this study, we investigated the impact of FMT for rCDI upon signalling through the
farnesoid X receptor (FXR)-fibroblast growth factor (FGF) pathway. Herein, we identify that in
addition to restoration of gut microbiota and bile acid profiles, FMT for rCDI is accompanied by a
significant, sustained increase in circulating levels of FGF19 and reduction in FGF21. These FGF
changes were associated with weight gain post-FMT, to a level not exceeding the pre-rCDI
baseline. Collectively, these data support the hypothesis that the restoration of gut microbial
communities by FMT for rCDI is associated with an upregulated FXR-FGF pathway, and highlight
the potential systemic effect of FMT.
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Introduction
Fecal microbiota transplantation (FMT) is a highly
effective therapy against recurrent Clostridioides diffi-
cile infection (rCDI). However, the mechanisms by
which FMT exerts its efficacy in rCDI remain unclear.
In recent years, restoration of pre-morbid gut bile acid
metabolism has become one of the better known
potential mechanisms supported by both human and
animal studies. Secondary bile acids inhibit C. difficile
vegetative growth, while certain primary bile acids
(and particularly taurocholic acid) promote
germination.1 It has been demonstrated that second-
ary bile acid concentrations are much reduced while
primary bile acid levels are elevated in rCDI patients
compared tohealthy controls, potentially perpetuating
C. difficile proliferation.2 Following FMT, which
restores the diversity and composition of the intestinal
microbiota, bile acid homeostasis is re-established.2
Furthermore, there is also evidence that the loss of
microbiota-derived bile-metabolising enzymes may
contribute to the pathogenesis of CDI both in mice
and in humans.3–5
Bile acid metabolism is not only regulated by
commensal bacteria, but also through farnesoid X
receptors (FXR), which are abundantly expressed
in the liver and ileum.6 In humans, the most
potent endogenous ligand for FXR is the primary
bile acid chenodeoxycholic acid (CDCA); the sec-
ondary bile acids deoxycholic acid (DCA) and
lithocholic acid (LCA) are moderate FXR ago-
nists, whilst the primary bile acid cholic acid
(CA) also has modest agonist activity.7 Upon
ileal FXR activation, fibroblast growth factor
(FGF)19 is secreted into the portal circulation,
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where it binds to the FGFR4/β Klotho receptor com-
plex on hepatocytes. This interaction acts as both a
negative feedback control on hepatic bile acid synth-
esis through inhibition, and also as amodulator of key
metabolic pathways involved in glucose, lipid, and
energy metabolism.8 Although both FGF19 and
FGF21 are involved in regulating multiple metabolic
processes, they have an inverse relationship that col-
lectively maintains metabolic homeostasis, since
FGF19 is produced during feeding while FGF21 is
secreted during fasting.9 Perturbation of FXR signal-
ling and altered FGF levels have been found in a
number of disease states, including type 2 diabetes,
metabolic syndrome and Crohn’s disease.10,11
Furthermore, surgically-induced weight loss is asso-
ciated with an increase in FGF19 and a decrease in
FGF21 levels.10
There is growing evidence from murine stu-
dies that altered interaction between the gut
microbiota and bile acids may directly affect
FXR signalling. Germ-free and antibiotic-trea-
ted mice have markedly reduced ileal Fgf15
gene expression (murine orthologue of human
FGF19).12 The resultant accumulation of tauro-
β-muricholic acid (an FXR antagonist) is
thought to be the link between alterations of
the gut microbiota and FXR signalling in mice.
However, given that this bile acid is only pre-
sent at very modest levels in humans, coupled
with the differences in FGF orthologues and
microbiota between humans and mice, extrapo-
lating these data to humans is problematic.
Presently, there are no human studies to our
knowledge examining the impact of antibiotic-
induced dysbiosis on FXR signalling. Given the
apparent key contribution of the microbiota-
bile acid axis to CDI pathogenesis, we investi-
gated the association between changes in bile
acid composition and FGF19 and 21 following
FMT for the treatment of rCDI in humans. To
do this, we analysed samples collected from a
recent randomised trial of capsulized vs colono-
scopic FMT for the treatment of rCDI.13 We
undertook metagenomic, metabonomic and
proteomic analyses for these samples, and cor-
related with weight changes following rCDI
eradication.
Results
Stool metagenome analysis
We have previously described that successful FMT
for rCDI is associated with both marked increases in
stool microbial diversity and altered microbial com-
munity composition to resemble that of healthy
donors, maintained up to at least 12 weeks post-
FMT.13 Further analysis here demonstrated that suc-
cessful FMT was particularly associated with enrich-
ment of a number of bacterial genera including
Bacteroides, Faecalibacterium, Ruminococcus,
Blautia and Eubacterium (all of which contain mem-
bers with bile acid-metabolising function) and loss of
Klebsiella, Escherichia and Veillonella (which gener-
ally lack these functions) (Supplementary Figure 1).7
Ultra-performance liquid chromatography-mass
spectrometry (UPLC-MS) stool bile acid profiling
Successful FMT was also associated with significantly
decreased stool levels of the primary bile acids CDCA
and CA, and significantly increased levels of the sec-
ondary bile acids DCA and LCA (Figure 1). In all
cases, these changes were observed at four weeks
post-FMT and were maintained at 12 weeks post-
therapy.
Proteomic analysis
Of 73 compared proteomic markers (Supplementary
Table 1), the differences were statistically significant
for only two: FGF19 andFGF21 (Figure 2). FGF19 had
significantly higher Normalized Protein eXpression
(NPX) values at weeks 4 and 12 compared with
screening, while FGF21 had significantly lower NPX
values at weeks 4 and 12 compared with screening.
There was no significant difference in the levels of
FGF19 and FGF21 between the groups receiving
FMT by either capsules or colonoscopy (data not
shown).
Differences in weight before and after FMT
Following successful FMT, there was a statistically
significant increase in mean BMI at 12 weeks fol-
lowing FMT compared to screening, but this did
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not exceed pre-rCDI baseline (mean BMI differ-
ence [95%CI], 0.5 [0.2, 0.8]; p = 0.003, Table 1.
Discussion
While it has already been observed that FMT in
humans with rCDI restores gut microbiota and
bile acid composition, we demonstrate for the
Figure 1. Effect of FMT for rCDI upon bile acid profiles.
A significant decrease in chenodeoxycholic acid (A) and cholic acid (B) is seen between screening and 4 weeks, and maintained up to
12 weeks post-FMT. A significant increase in lithocholic acid (C) and deoxycholic acid (D) is observed between screening and
4 weeks, and maintained up to 12 weeks post-FMT. X-axis depicts time, and y-axis depicts relative intensity of each bile acid. Pre-
FMT = screening; week 4 = 4 weeks after fecal microbiota transplantation (FMT); week 12 = 12 weeks post-FMT.
Figure 2. Normalized Protein eXpression (NPX) values for serum fibroblast growth factor (FGF)19 (A) and FGF21 (B) over time.
There is a statistically significant increase in FGF19 level 4 and 12 weeks after FMT compared to screening, while a statistically
significant decrease in FGF21 level is observed 4 and 12 weeks following FMT. X-axis depicts time, and y-axis depicts relative
quantification of respective FGF. Circles represent mean; error bars represent standard deviation.
Table 1. Comparison of the mean body mass index (BMI) over
time. At week 4, the mean BMI was not significantly different
from the mean BMI prior to FMT. At week 12, patients had
significantly higher BMI relative to pre-FMT, but did not exceed
pre-rCDI baseline.
Mean BMI Difference (95% CI) p value
Week 4 – Pre-FMT 0.0 (−0.3, 0.3) 0.84
Week 12 – Pre-FMT 0.5 (0.2, 0.8) 0.003
Week 12 – Week 4 0.4 (0.1, 0.8) 0.006
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first time that this procedure is also associated
with activation of ileal FXR signalling, manifested
by increased FGF19 and reduced FGF21 expres-
sion. CDCA is the most potent endogenous ligand
for FXR, although the secondary bile acids DCA
and LCA are also moderate FXR agonists. Our
data suggest that the reduced level of a potent
FXR agonist (CDCA) is offset by increased levels
of two moderate FXR agonists (DCA and LCA),14
with a net upregulation of the ileal FXR-FGF path-
way following successful FMT. Some phases of this
bile acid transformation process (e.g. 7-α dehy-
droxylation) occur within the colon, implying
that for secondary bile acids to affect ileal FXR
signaling, they must be reabsorbed in the colon
and re-secreted in bile into the small intestine.15
Although metabolism of bile acids in the gut is a
bacterially-driven process,7 further studies are
needed to examine the specific contribution of
different bacteria to this process.
In addition to its well-defined roles in the reg-
ulation of metabolism and bile acid production,
there is also evidence in how FXR signalling plays
a role in other systemic processes relevant to CDI.
For example, FXR activation has been shown to
inhibit bacterial overgrowth and block mucosal
injury in mouse ileum,16 and is associated with
reduced expression of key cytokines (including
TNF-α and IL-1β) that regulate the host innate
immune response.17 Moreover, the inflammatory
response or C. difficile itself could reciprocally
inhibit activation of FXR and its target FGF
genes, and this therefore merits further study.
Although our data are consistent with previous
studies in observing restoration of the gut micro-
biota and bile acid composition post-FMT for
rCDI, there is no direct demonstration that this
pathway is a key mechanism underpinning the effi-
cacy of FMT for rCDI. In addition, it is not clear if
the observed weight gain following FMT is directly
mediated through changes in FGF19/21 levels.
Future mechanistic studies involvingmouse models
of CDI would be required to determine causality,
and such studies should consider including analysis
of the effect of FMT upon FXR signalling. Should
these experiments validate our preliminary find-
ings, the bile acid-FXR axis may become a novel
therapeutic target for the treatment of rCDI. There
are already some data that would appear to support
this strategy; specifically, the potent FXR agonist
obeticholic acid (INT-747) has been shown to dis-
play anti-C. difficile potential in murine models of
CDI.18 However, the benefits and risks of synthetic
FXR ligands require further evaluation.
In conclusion, our data suggest that FMT is asso-
ciated with upregulation of the bile acid-FXR-FGF
signalling pathway, and this may possibly explain the
rapid improvement in energy and well-being many
patients experience following FMT. Although these
findings are intriguing, we acknowledge several lim-
itations, including small sample size, short follow-up
period, the observational nature of the data, lack of
mucosal inflammatory protein expression data, and
non-consideration of diet or host genetics. Insights
gleaned from better understanding of FMT mechan-
isms of action using a multi-omics approach could
enable development of tailored therapies that target
key signaling pathways or specific constituents of
those pathways that may regulate host defence to
circumvent various concerns surrounding FMT.
Materials and methods
Patient clinical data, sample collection and
storage
Participants (n = 116) in the capsule vs colonoscopy-
delivered FMT trial were included this pilot study.13
Blood and stool samples were collected, and body
mass indices (BMI) documented at screening and
subsequent follow-up visits at weeks 4 and 12 after
FMT. Of the 64 patients recruited from Edmonton,
43 had complete sets of archived blood samples and
were subjected to proteomic analyses using the Olink
inflammation panel. Of these 43 patients, 23 were
chosen at random to have their stool samples
undergo microbial composition analysis by shotgun
metagenomics sequencing. From these 23 patients, 17
randomly-selected patients had stool bile acid profil-
ing by ultra-performance liquid chromatography-
mass spectrometry (UPLC-MS). Patient baseline
characteristics are shown in Table 2. The metage-
nomic, metabonomic, and proteomic results were
correlated with weight changes following rCDI era-
dication. This study was approved by the research
ethics board of the University of Alberta (Pro49006).
4 T. MONAGHAN ET AL.
Stool metagenomics
Whole-genome shotgun sequencing was per-
formed as previously described.13 More specifi-
cally, taxonomic classification of reads from
each library was conducted with Kraken.19 The
database used consisted of all bacteria, archaea,
viruses, fungi, and protozoa full-length genomes
from NCBI RefSeq, the human genome assembly
GRCh38, and reference bacterial assemblies
from the Human Microbiome Project.20 Read
assignments were filtered with Kraken-filter
using a threshold of 10%.
UPLC-MS profiling of fecal bile acids
Sample preparation was performed using proto-
cols as previously-described.21 Bile acid analysis
of faecal extracts was performed using ACQUITY
UPLC (Waters Ltd, Elstree, UK) coupled to a Xevo
G2 Q-ToF mass spectrometer equipped with an
electrospray ionization source operating in nega-
tive ion mode (ESI-), using the method described
by Sarafian and colleagues.22 Waters raw data files
were converted to NetCDF format and data
extracted using the XCMS (v1.50) package in R
(v3.1.1) software. Probabilistic quotient
normalisation23 was used to correct for dilution
effects and chromatographic features with coeffi-
cient of variation higher than 30% in the QC
samples were excluded from further analysis. The
relative intensities of the features were corrected to
the dry weight of the faecal samples.
Proteomics
The relative levels of serum inflammatory proteins
were analyzed with Olink® Inflammation I panel
(Olink Proteomics AB, Uppsala, Sweden) using
Proximity Extension Assay (PEA) according to the
manufacturer’s instructions.24,25 A list of the 92
inflammation-related markers is listed in
Supplementary Table 2. In brief, serum samples
(1µL) were incubated with 92 oligonucleotide labelled
antibody probe pairs that bind to their respective
target in the sample. A PCR reporter sequence was
formed by a proximity dependent DNA polymeriza-
tion event and was subsequently detected and ampli-
fied using a microfluidic real-time PCR instrument
(Biomark HD, Fluidigm). Data was then quality con-
trolled and normalized using an internal extension
control and an inter-plate control, to adjust for intra-
and inter-run variation. The final assay read-out is
presented in Normalized Protein eXpression (NPX)
values, which is an arbitrary unit on a log2-scale
where a high value corresponds to a higher protein
expression. All assay validation data (detection limits,
intra- and inter-assay precision data, etc) are available
on the manufacturer’s website (http://www.olink.
com). Samples failing technical quality controls or
that fell below lower limits of detection were excluded
from analyses.
Statistical analysis
Full methodology for statistical analysis is pro-
vided in the Supplementary Material.
Table 2. Patient baseline characteristics.
Variable
Blood proteomics analysis
(n = 43)
Stool bile acid analysis
(n = 17)
Age, mean (SD), y 58.8 (19.2) 58.1 (17.1)
Female, No. (%) 27 (62.8%) 13 (76%)
Charlson Comorbidity Index score, median (Q1-Q3) 3 (1–5) 3 (1–4)
Immunosuppressed patients, No. (%) 5 (11.6%) 0
BMI, mean (SD) 25.9 (5.9) 27.5 (6.0)
PPI use prior to FMT, No. (%) 5 (11.6%) 2 (11.7%)
Hemoglobin, median (Q1-Q3), g/dL 13.8 (13.0–14.4) 13.9 (13.1–14.5)
White blood cell count, median (Q1-Q3),/uL 7100 (5850–8500) 6750 (5620–8130)
Albumin, median (Q1-Q3), g/dL 4.0 (3.8–4.3) 4.0 (3.9–4.3)
C-reactive protein, median (Q1-Q3), mg/dL 0.29 (0.085–0.10) 0.30 (0.075–0.89)
Creatinine, median (Q1-Q3), mg/dL 0.75 (0.66–0.87) 0.74 (0.66–0.94)
Capsule delivered FMT, No. (%) 25 (58.1%) 11 (64.7%)
Abbreviations: BMI, body mass index; FMT, fecal microbiota transplantation; PPI, proton pump inhibitor; Q1, first quartile; Q3, third quartile.
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Abbreviations
BMI body mass index
CA cholic acid
CDI Clostridioides difficile infection
CDCA chenodeoxycholic acid
DCA deoxycholic acid
FGF fibroblast growth factor
FMT fecal microbiota transplantation
FXR farnesoid X receptor
LCA lithocholic acid
rCDI recurrent Clostridioides difficile infection
NPX Normalized Protein eXpression
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